Pharmaceutical Gelatin Market - By Product (Type A, Type B), Source (Porcine, Bovine, Fish, Poultry), Function (Stabilizers, Thickeners, Gelling Agents, Film Forming), Application (Capsules, Tablets, Absorbable hemostats), Global Forecast 2023-2032

Pharmaceutical Gelatin Market size

Pharmaceutical Gelatin Market size was valued at around USD 1.1 billion in 2022 and is estimated to reach USD 1.9 billion by 2032. Increasing burden of chronic disease is expected to increase the demand for pharmaceutical-grade gelatin.
 

Also, expanding developments of gelatin nanoparticles in medications and vaccines are driving the market expansion. Growing use of gelatin in cosmetics, intrinsic activities, biomedical applications such as wound treatment & healing, and bone substitutes are observed in several studies with new developments in the market. For instance, according to the National Institute of Health (NIH) study, it was found that bovine hydroxyapatite-gelatin-hydroxypropyl methylcellulose with alendronate was utilized as injectable bone substitute (IBS) for the treatment of bone with osteoporosis in animal model.
 

Pharmaceutical gelatin is generated from animal skin, white connective tissues, and bones. They comprises high molecular weight, thermo-reversible, biocompatible and are water soluble in nature. It is a common excipient used in the manufacture of hard capsules and soft gels. Furthermore, it is utilized as a binder in tablets, blood plasma substitutes among other applications.
 

COVID-19 Impact

The COVID-19 pandemic was an unprecedented event impacting public health and led to an incremental surge in the number of hospitalizations.  The coronavirus outbreak proliferated the disease burden and hampered several global businesses including the healthcare sector, during 2020 & initial phase of 2021.  This resulted in delays or postponing several medical and diagnostics procedures. During the COVID-19 pandemic, there was a gelatin shortage, which impacted the global pharmaceutical gelatin industry.  Drug producers rely on animal sources for gelatin, especially in capsule manufacturing, therefore, disturbances in this cycle were observed at the initial stage of the pandemic owing to the lockdown & restrictions on movements, travel limitations, abattoirs, and cattle transportation. 
 

Furthermore, restrictions on employee movement and a brief halt on manufacturing units impacted gelatin productivity.  As a result, the manufacturing valued chain was impeded throughout the pandemic period.  However, with the relaxation of regulations and a surge in demand for gelatin in the pharmaceutical industry, the global market expanded in late 2020.
 

Pharmaceutical Gelatin Market Trends

The increasing initiatives from major market participants to develop revolutionary gelatin capsule shells using innovative technologies is opening up multiple opportunities for market progress. For example, etectRx, Inc., a digital health startup, has begun research to assess antiretroviral drug adherence among prescription opioid users infected with the human immunodeficiency virus (HIV). The ID-Cap System consists of a hard gelatin capsule with an embedded ingestible wireless sensor and a wearable reader will be used in the "MyTPill" experiment to monitor patient adherence. Such initiatives by market players is projected to expand the usage of gelatin in the production of hard gelatin capsules (ID-Cap), thereby enhancing the market revenue.
 

Pharmaceutical Gelatin Market Analysis

Based on type, the pharmaceutical gelatin market is segmented as type A and type B. The Type B category dominated the market with a business share of 65.4% in the year 2022. The dominance is due to a variety of factors including cost-effective production due to the availability of raw materials and its use in a variety of applications across the pharmaceutical industry. Also, type B gelatin provide increased gel storage stability than low-bloom gelatin that enables industry players to opt for such product type, thereby augmenting the segment landscape.
 

Based on source, the pharmaceutical gelatin market is segmented into porcine, bovine, fish, and poultry. Porcine source dominated the market with revenue of 520.5 million in 2022. The quick manufacturing cycle, cost-effective production and utilization of porcine based products in pharmaceutical industry are few significant aspects for driving the segment share. For instance, according to the National Health Service (NHS), the use of porcine-based products as a stabiliser in various vaccines and capsules to maintain efficacy and safety, particularly during and after storage.
 

Based on function, Based on function, the pharmaceutical gelatin market is segmented into stabilizers, thickeners, gelling agents, film forming, adhesion and other functions. The stabilizers segment is expected to show considerable growth of 7.4% during the analysis period. The rising use of gelatin as a vaccine stabilizer is projected to fuel segment outlook. Few vaccines contain a stabilizer made from well processed gelatin with minimal endotoxin levels that help in lowering the risk of side effects and assuring patient safety. It also aids in the stability of lyophilized (freeze-dried) products.
 

Based on application, the pharmaceutical gelatin market is segmented into capsules, tablets, absorbable haemostats & other applications. Further, the capsules segment are sub-divided into hard and soft capsules. The capsules segment dominated the market in 2022 and is estimated to reach 970.6 million by 2032. The gelatin softgel capsule offer several advantages such as ease of swallowing, longer shelf life and taste masking will propel the segment development. Moreover, high preference of pharmaceutical manufacturer for gelatin based empty capsules for different formulations due to non-reactive nature and ease of use is anticipated to supplement the capsule market share.
 

North America pharmaceutical gelatin market is anticipated to witness a 41.2% market share in 2022. Presence of key market participants along with developed healthcare infrastructure are among the factors responsible for North America's prominent position in the pharmaceutical gelatin industry. Also, rising gelatin capsule manufacturing services in North America is one of the major factor for market expansion. For instance, in March 2021. CapsCanada, a capsule technology company, announced a new service for the creation of liquid-filled hard capsules. The new service is aimed to support the entire manufacturing process, from product discovery and formulation to full-scale production. Such activities are projected to expand the use of pharmaceutical gelatin for capsule filling in formulation development.
 

Pharmaceutical Gelatin market Share

Some of the major market players operating in the pharmaceutical gelatin industry are:

• NITTA GELATIN, INC
• GELITA AG
• Tessenderlo Group (PB Leiner)
• Weishardt
• Trobas Gelatine B.V
• Lonza
• India Gelatine & Chemicals Ltd
• Gelnex
• Juncà Gelatines SL
• ITALGEL S.p.A

These players focus on strategic partnerships, new product launch & commercialization for market expansion. Furthermore, these players are heavily investing in research that allows them to introduce innovative products and garner maximum revenue in the market.
 

Pharmaceutical Gelatin market News:

• In May 2022, Capsugel enhanced its titanium dioxide-free capsule line by offering white firm gelatin capsules without titanium dioxide (TiO2-free). The new titanium dioxide-free capsule is based on crystalline salts and provides similar masking and whitening as titanium dioxide capsules. The product provides great light shielding and opacity.
   

In January 2022, Terasaki Institute for Biomedical Innovation (TIBI) collaborated with Rousselot, a Darling Ingredients company. The collaboration aimed to advance gelatin-based therapies with Rousselot's X-Pure modified gelatin range. This strategy is expected to enhance their long-term business relations.
 

The pharmaceutical gelatin market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Type, 2018 - 2032 (USD Million)

• Type A
• Type B

By Source, 2018 - 2032 (USD Million)

• Porcine
• Bovine
• Fish
• Poultry  

By Function, 2018 - 2032 (USD Million)

• Stabilizers
• Thickeners
• Gelling agents
• Film forming
• Adhesion
• Other functions

By Application, 2018 – 2032 (USD Million)

• Capsules
  • Hard capsules
  • Soft capsules
• Tablets
• Absorbable hemostats
• Other applications

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific 
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa